New Stem Cell Research
Adult stem cells deployments in the United States are considered investigational. The FDA (Food and Drug Administration) has not approved the use of adult stem cells for any indication. Insurance companies almost never cover therapy using adult stem cells. Most adult stem cell deployments are done under the supervision of an Investigational Review Board (IRB).
The IRB helps ensure that the investigations are safe and appropriately performed. We strongly recommend that potential patients seek practices working with IRB oversight. Some of the disorders with IRB approved protocols are:
- Orthopedic problems such as osteoarthritis, post traumatic arthritis and soft tissue injuries.
- Auto-immune or connective tissue disorders such as rheumatoid arthritis and scleroderma.
- Neurologic disorders such as multiple sclerosis, Parkinson’s disease or stroke.
- Lung problems such as chronic obstructive pulmonary disease (COPD).
- Gastrointestinal disease such as Crohn’s disease or auto-immune hepatitis.
- Cardiac disease such as congestive heart failure (CHF).
- Urinary disease such as interstitial cystitis or erectile dysfunction.
- Eye disease such as macular degeneration, retinitis pigmentosa and diabetic retinopathy.
- Dermatologic conditions such as hair loss and lichen sclerosis.
Many of these protocols can be adapted to other disorders not specifically mentioned. There are new deployment protocols coming out every month. If you do not see your area of concern please contact us for availability.